SOPH - Public offerings

Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted all proposals on the agenda, electing Dr. Jurgi Camblong as the Executive Chairman of the Board of Directors with 99.79% of the votes, and Ross Muken as a member of the Board of Directors for the first time with 99.88% of the votes. Mr. Muken will assume the role of Chief Executive Of

BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares at the public offering price, less the underwriting discounts and commissions. The Company sold 12,104,900 ordinary shares at a price to the

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,578,900

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offer

Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the BoardBOSTON and ROLLE, Switzerland, June 10, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes first announced in January 2026. The Board has appointed Ross Muken, currently President, as Chief Executive Officer, effective July 1, 2026, and nominated him for election as a member of the Board of Directors. Furthermore, as

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.

BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue grew 27% year-over-year to $17.0 million; Constant currency revenue excluding COVID-related revenue also grew 27% year-over-yearGross margins were 70% on a reported basis and 73% on an adjusted basisOperating loss was $18.9 million on a reported basis and $13.3 million on an adjusted basisChange in cash and cash equivalents and term deposits (cash burn) improved 11% year-over-year

Fourth Quarter Revenue Growth Accelerates; Operating Losses Notably Moderate SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022. Recent Highlights Revenue for the full-year 2022 was $47.6 million, representing year-over-year growth of 18% on a reported basis. 2022 constant currency revenue growth excluding COVID-19-related revenues was 39% Revenue was $13.4 million for the fourth quarter, representing a 22% increase on a reported basis over the corresponding period of 2021. Constant currency revenue growth excluding COVID-19-related revenues was

BOSTON and LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Revenue for the third quarter of 2022 was $11.6 million, representing year-over-year growth of 12%; constant currency revenue growth excluding COVID-19-related revenues was 40%Expanded strategic partnership with Microsoft to improve healthcare workflows globally and enable the increased adoption of data-driven medicineSomatic Oncology portfolio strength underscored by triple-digit growth in HRD analysis volume and continued mo

BOSTON and LAUSANNE, Switzerland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Revenue for the second quarter of 2022 was $11.7 million, representing year-over-year growth of 15%; constant currency revenue growth excluding COVID-19-related revenues was 36%Gross margin was 65% for the second quarter of 2022 compared to 61% for the second quarter of 2021; adjusted gross margin was a record 67% for the second quarter of 2022 compared to 62% for the second quarter of 2021Fiscal year 2022 constant currency revenue growth

Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed BOSTON and LAUSANNE, Switzerland, March 15, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), a leader in data-driven medicine, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Revenue for full year 2021 was $40.5 million, representing year-over-year growth of 42%, and revenue for the fourth quarter of 2021 was $10.9 million, representing year-over-year growth of 40%Total recurring platform customers grew to 382 as of December 31, 2021 up from 314 as of December 31, 2020, and 375 as of September 30, 2021, while net dollar re

BOSTON and LAUSANNE, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), today reported financial results for the third quarter ended September 30, 2021. Recent Highlights Revenue was $10.4 million for the third quarter, representing a 45% increase over the corresponding period of 2020Following a previous letter of intent with GE Healthcare, executed a final Master Alliance Agreement under which we will be working together with GE on a variety of oncology opportunities in the healthcare market and will collaborate on different initiatives and projectsTotal recurring platform customers grew from 367 in the second quarter of this year to 375 customers in the th

BOSTON and LAUSANNE, Switzerland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (NASDAQ:SOPH), today reported financial results for the three months ended June 30, 2021. Recent Highlights Revenue was $10.2 million for the second quarter, representing a 72% increase over the corresponding period of 2020Increased total customer base of hospitals, labs, and biopharma institutions to 780 customers during the second quarter, up from 750 in the first quarter of 2021Strengthened balance sheet by raising approximately $217 million in net proceeds from the initial public offering in July 2021 and an additional $20 million in gross proceeds from a private placement investment from